The present invention provides a new use of a compound of formula (I) or a pharmaceuticallyacceptable salt or solvate salt thereof, wherein: G is selected from a group consistingof: phenyl, pyridyl, benzothiazolyl, indazolyl； p is an integer ranging from0 to 5； R is independently selected from a group consisting of: halogen,hydroxyl, cyano, C1-4alkyl, haloC1-4alkyl, C alkoxy, haloCalkoxy,Calkanoyl； or corresponds to a group R； Ris hydrogen or C alkyl； R I s Calkyl； Ris hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromaticgroup, or a 8- to 11-membered bicyclic group, any of which groups is optionallysubstituted by 1, 2, 3 or 4 substituents selected from the group consisting of:halogen, cyano, Calkyl, haloCalkyl, Calkoxy,Calkanoyl； R is a moiety selected from the group consistingof: isoxazolyl, -CH-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl,thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionallysubstituted by one or two substituents selected from: halogen, cyano, Calkyl,haloCalkyl, Calkoxy, Calkanoyl；and when R is chlorine and p is 1, such R is not present inthe ortho position with respect to the linking bond to the rest of the molecule；and when R corresponds to R, p is 1； in the manufacture ofa medicament for the treatment of a somatoform disorder such as body dysmorphicdisorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating,paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis,autism, a movement disorder including Tourette's syndrome； and in themanufacture of a medicament for the treatment of premature ejaculation.
